Cencora, Inc.: EPS $4.66 vs $4.58 expected; revenue $88.4B vs $88.0B
Key Facts
Q4 FY2026 results
| Metric | Actual | Estimate | Surprise | Year ago |
|---|---|---|---|---|
| EPS (USD) | 4.66 | 4.58 | +1.7% | 3.84 |
| Revenue (USD bn) | 88.35 | 87.95 | +0.5% | 83.73 |
Recent reports: actual vs estimate
| Reported | Period | EPS (USD) | Estimate | Surprise | Revenue (USD bn) | Estimate | Surprise |
|---|---|---|---|---|---|---|---|
| Nov 4, 2026 | Q4 FY2026 | 4.66 | 4.58 | +1.7% | 88.35 | 87.95 | +0.5% |
| Aug 5, 2026 | Q3 FY2026 | 4.48 | 4.35 | +3.0% | 84.75 | 84.31 | +0.5% |
| May 6, 2026 | Q2 FY2026 | 4.75 | 4.82 | −1.5% | 78.36 | 81.09 | −3.4% |
| Feb 4, 2026 | Q1 FY2026 | 4.08 | 4.05 | +0.7% | 85.93 | 86.06 | −0.1% |
| Nov 5, 2025 | Q4 FY2025 | 3.84 | 3.79 | +1.3% | 83.73 | 83.46 | +0.3% |
| Aug 6, 2025 | Q3 FY2025 | 4.00 | 3.85 | +3.9% | 80.66 | 80.09 | +0.7% |
| May 7, 2025 | Q2 FY2025 | 4.42 | 4.11 | +7.5% | 75.45 | 75.68 | −0.3% |
| Feb 5, 2025 | Q1 FY2025 | 3.73 | 3.50 | +6.6% | 81.49 | 78.31 | +4.1% |
Source: Figures from the EL7 database. Estimates are the analyst consensus carried by our data vendor (FMP), not official figures.
Cencora, Inc. results: EPS $4.66 vs $4.58 expected; revenue $88.4B vs $88.0B. The results cover the company's Q4 FY2026. EPS came in above analysts' estimate by 1.7%; revenue above the estimate by 0.5%.
Revenue was up 5.5% from $83.7 billion a year earlier (Q4 FY2025). EPS was up 21.4% from $3.84 a year earlier. On its record, EPS topped analysts' estimates in 6 of 7 earlier comparable reports.
What the results mean
Cencora’s results reflect growth in healthcare solutions across the United States and international markets, with the oncology services platform acquisition playing a prominent role in expanding gross margin. Increased sales of lower-margin diabetes and obesity medicines partially offset that expansion, highlighting the importance of business mix alongside distribution growth.
The improvement in reported operating profit requires separating accounting effects from business performance. The absence of the PharmaLex goodwill impairment charge helped reported results, while adjusted operating expenses increased because of the acquired business. Acquisition financing also increased interest costs, pairing its operating contribution with financing burdens.
Management emphasized expanding its medical practice management services platform and sharpening the portfolio, alongside bringing specialty businesses together under a new operating model. This places specialty services integration and responsiveness to customer needs at the center of interpreting company performance, alongside pharmaceutical distribution.
What to watch on the earnings call: Integration of the oncology services platform and its contribution to margins and expenses, the effect of the diabetes and obesity medicine sales mix on profitability, and acquisition financing costs. Details of bringing specialty businesses together under the new operating model also merit attention, including implications for customer service and operational execution.
For the full analysis of Cencora, Inc. stock — valuation, scores and financial statements — see the stock page linked with this story.